OverviewSuggest Edit

Samsung Biologics is a contract development and manufacturing organization. It provides cell-line development to commercial manufacturing of drug substances and products. The company offers cGMP (Current Good Manufacturing Practice) facilities providing clinical and commercial products based on mammalian cell culture.
TypePublic
Founded2011
HQKR
Websitesamsungbiologics.com
Employee Ratings3.9
Overall CultureD

Latest Updates

Employees (est.) (Mar 2021)3,247(+19%)
Share Price (Nov 2021)₩820 K
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Samsung Biologics

John Rim

John Rim

President & CEO
Dong Joong Kim

Dong Joong Kim

Senior Vice President & Managing Director
Seok Woo Jeong

Seok Woo Jeong

Independent Director
Jo Kwon

Jo Kwon

Independent Director
Kun Nyoung

Kun Nyoung

Independent Director
Eunice Kyunghee Kim

Eunice Kyunghee Kim

Independent Director
Show more

Samsung Biologics Office Locations

Samsung Biologics has an office in
Show all (1)

Samsung Biologics Financials and Metrics

Samsung Biologics Revenue

Market capitalization (10-Nov-2021)

54.2t

Closing stock price (10-Nov-2021)

820.0k
Samsung Biologics's current market capitalization is ₩54.2 t.
Show all financial metrics

Samsung Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Samsung Biologics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Samsung Biologics Online and Social Media Presence

Embed Graph

Samsung Biologics Company Culture

  • Overall Culture

    D

    57/100

  • CEO Rating

    F

    50/100

  • Compensation

    D

    55/100

Learn more on Comparably

Samsung Biologics News and Updates

Samsung Biologics Reports Third Quarter 2021 Financial Results

Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. Stable supply, strong operational excellence and a high utilization rate across all plants. Active investment on expansion, pre-sales...

Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND. Samsung Biologics to offer a seamless, end-to-end CDMO service with support from its San Francisco R&D Center. COLLEGE...

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated...

Samsung Biologics Reports Second Quarter 2021 Financial Results

Q2'21 revenue of KRW 412.2 billion increased 34% compared to Q2'20. Q2'21 operating profit of KRW 166.8 billion increased 105.7% compared to Q2'20. Stable business operations and a high utilization rate across all plants Continuous investments to deliver the company's future growth plans...

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ --...

Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services

Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish...
Show more

Samsung Biologics Frequently Asked Questions

  • When was Samsung Biologics founded?

    Samsung Biologics was founded in 2011.

  • Who are Samsung Biologics key executives?

    Samsung Biologics's key executives are John Rim, Dong Joong Kim and Seok Woo Jeong.

  • How many employees does Samsung Biologics have?

    Samsung Biologics has 3,247 employees.

  • Who are Samsung Biologics competitors?

    Competitors of Samsung Biologics include WuXi Biologics, Pharmaron and Kindeva Drug Delivery.

  • Where are Samsung Biologics offices?

    Samsung Biologics has an office in.

  • How many offices does Samsung Biologics have?

    Samsung Biologics has 1 office.